Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527273 | PMC |
| http://dx.doi.org/10.1056/NEJMms1611497 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nuanced Public Support for Rationing Treatments by Withdrawing and Withholding Due to Negative Reimbursement Decisions.
J Bioeth Inq
September 2025
Swedish National Centre for Priorities in Health, Department of Health, Medicine, and Caring Sciences, Linköping University, 581 83, Linköping, Sweden.
When treatments are deemed not to be cost-effective and face non-reimbursement, policymakers in publicly funded healthcare systems may decide to ration treatments by withholding it from future patients. However, they must also address a critical question: should they also ration treatments by withdrawing it from patients already having access to the treatment, or is there an ethical difference between withdrawing and withholding treatments? To explore this question, we conducted a behavioural experiment (n=1404), examining public support for withdrawing and withholding treatments in reimbursement decisions across eleven different circumstances. Overall, public support for rationing by withdrawing and withholding was low, with no general perceived difference between withdrawing and withholding treatments.
View Article and Find Full Text PDFWhen Skin Reactions Interrupt Bone Therapy: Severe Cutaneous Adverse Reaction to Romosozumab Leading to Treatment Discontinuation.
Eur J Case Rep Intern Med
August 2025
General medicine department, Universidad de Cartagena, Cartagena, Colombia.
Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild.
Case Report: We present a case of a 71-year-old Colombian woman with osteoporosis at very high risk of fractures with no relevant history of drug allergies.
Multidisciplinary team management of caesarean scar ectopic pregnancy progressing to a live birth and caesarean hysterectomy at 34 weeks: A case report.
Case Rep Womens Health
October 2025
The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China.
Progression of a caesarean scar ectopic pregnancy (CSEP) to a live birth is exceptionally rare. Whether the placenta should be removed during a caesarean section for patients with a CSEP complicated by severe placenta accreta spectrum remains unclear. This report presents the case of a 42-year-old multigravida with two prior caesarean sections who presented with CSEP at 6 weeks.
View Article and Find Full Text PDFNOTIFICATION: Laparoscopic Ventral Mesh Rectopexy in Male Patients with Internal or External Rectal Prolapse.
Colorectal Dis
September 2025
A.E. Owais, H.
View Article and Find Full Text PDF